Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents

Published:2024-05-24 Issue:7 Volume:34 Page:583-592
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Aboul-Soud Mourad A. M.¹^ORCID,Al-Sheikh Yazeed A.¹,Ghneim Hazem K.¹,Supuran Claudiu T.²^ORCID,Carta Fabrizio²^ORCID

Affiliation:

1. Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia

2. NEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, Sesto Fiorentino, Florence, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2024.2355247

Reference85 articles.

1. Kinase drug discovery 20 years after imatinib: progress and future directions

2. Protein kinases — the major drug targets of the twenty-first century?

3. Protein Kinase Inhibitors as a Therapeutic Modality

4. The origins of protein phosphorylation

5. The Protein Kinase Complement of the Human Genome

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP